98%
921
2 minutes
20
The wide range and complexity of cosmetic formulations currently available on the market poses a challenge from an analytical point of view. In addition, during cosmetics manufacture, impurities coming from raw materials or formed by reaction of different organic compounds present in the formulation may be present. Their identification is mandatory to assure product quality and consumer health. In this work, micro-matrix solid-phase dispersion (μMSPD) is proposed as a multi-target sample preparation strategy to analyze a wide number of unexpected families of compounds including polycyclic aromatic hydrocarbons (PAHs), pesticides, plasticizers, nitrosamines, alkylphenols (APs), and alkylphenol ethoxylates (APEOs). Analytical determination was performed by gas chromatography-mass spectrometry (GC-MS) for the determination of 51 target compounds in a single run, whereas liquid chromatography tandem mass spectrometry (LC-MS/MS) was employed for the analysis of six APs and APEOs. Both methodologies were successfully validated in terms of linearity, accuracy, and precision in leave-on and rinse-off cosmetics. Limits of detection (LODs) were calculated in the low ng g, showing their suitability to determine trace levels of impurities and banned compounds with different chemical natures, providing useful tools to cosmetic control laboratories and companies.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123312 | PMC |
http://dx.doi.org/10.3390/molecules26092504 | DOI Listing |
Mol Divers
September 2025
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Tilorone, a 9-fluorenone scaffold-based molecule, is a known broad-spectrum antiviral with an IC of 180 nM against SARS-CoV-2, but its mechanism is not known. In the present study, we found it to have weak activity against PLpro (IC = 30.7 ± 7.
View Article and Find Full Text PDFJ Hand Surg Am
September 2025
Department of Orthopaedic Surgery, SUNY Downstate Health Sciences University, Brooklyn, NY.
Purpose: This study aimed to evaluate how major US health care policy changes have influenced long-term Medicare reimbursement trends for upper-extremity flap and microvascular procedures from 2002 to 2023.
Methods: Reimbursement data for 28 common flap and microvascular procedures were extracted from the Medicare Physician Fee Schedule database using Current Procedural Terminology codes. Adjustments for inflation were made using the Consumer Price Index.
Mol Pharm
September 2025
Johnson & Johnson, Translational PK/PD & Investigational Toxicology, Spring House, Pennsylvania 19002, United States.
Human intestinal permeability is a key determinant of the oral fraction absorbed () of active pharmaceutical ingredients (APIs). This study evaluated the ability of an in-house canine Mdr1 (cMdr1) knockout (KO) Madin-Darby Canine Kidney (MDCK) cell line to correlate apparent permeability () with human small intestinal permeability (). values of 16 reference compounds with high, medium, or low permeabilities were measured in the in-house cMdr1 KO MDCK protocol under pH gradient (6.
View Article and Find Full Text PDFNutr Rev
September 2025
Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran 1417613151, Iran.
Context: Cardiovascular protective properties of berries have been reported in numerous studies. Berries and their bioactive compounds may also be effective for improving body composition and anthropometric indices.
Objective: This systematic review and meta-analysis were aimed to investigate the effect of berries on anthropometric markers.
Expert Opin Ther Pat
September 2025
Dipartimento di Scienze per la Qualità della Vita, Alma Mater Studiorum - Università di Bologna, Rimini, Italy.
Introduction: Topoisomerase (topo) II inhibitors continue to represent a promising approach in anticancer therapy, although their clinical application is hampered by drug resistance and dose limiting toxicities.
Area Covered: We performed a critical analysis of patent literature from January 2016 to January 2025 on topo II inhibitors in oncology using the online databases Espacenet, Wipo, and Google patent.
Expert Opinion: Substantial progress in the development of novel topo II inhibitors through synthetic chemistry, natural product isolation, molecular modification, and in silico screening was recorded.